Intelligence · Clinical Development
Pipeline search results
Programs matching “chidamide” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 19 pipeline programs matching "chidamide" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
Daihong Liu
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
1 trial -
CSIIT-Q115
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Small Cell Lung Cancer
1 trial -
Chidamide
Sun Yat-sen University
Peripheral T-cell Lymphoma
1 trial -
Chidamide
The First People's Hospital of Lianyungang
Neuroendocrine Tumors
2 trials -
Chidamide
Biotech Pharmaceutical Co.,
Relapsed or Refractory Peripheral T-cell Lymphoma
1 trial -
Chidamide
Biotech Pharmaceutical Co.,
Hepatocellular Carcinoma (HCC)
1 trial -
Chidamide + Tislelizumab + chemotherapy (CapeOX )
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Adenocarcinoma
1 trial -
Chidamide Combined with NKG2D CAR-NK Cell Therapy
The First People's Hospital of Lianyungang
HIV (Human Immunodeficiency Virus)
1 trial -
Chidamide combined with Duvillisib
The First People's Hospital of Lianyungang
Peripheral T Cell Lymphoma
1 trial -
S2023-056-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
S2023-413-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Acute Myeloid Leukemia
1 trial -
chidamide + camrelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
chidamide，fulvestrant
The First People's Hospital of Lianyungang
Hormone Receptor-positive Advanced Breast Cancer
1 trial -
surufatinib + fulvestrant + chidamide
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
CMOP+Chidamide
The First People's Hospital of Lianyungang
Newly Diagnosed Peripheral T-cell Lymphoma
1 trial -
Chidamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
Chidamide
Hospital Authority, Hong Kong
AML
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.